Etanercept-Induced Interstitial Lung Disease in a Patient with Plaque Psoriasis
Abstract
Etanercept is one of the biologic drugs approved for the treatment of psoriasis. Despite its wide use and proven efficacy, few cases of pulmonary toxicity have been reported.
We present a patient with psoriasis vulgaris medicated with etanercept. Seven months after its start, the patient developed productive cough, with no fever or constitutional symptoms. The thoracic computerized tomography revealed a pattern of bilateral dense micronodules, with predominance in the superior lobes. After suspension of etanercept, there was symptomatic and imaging resolution, without the need for additional pharmacological treatment. We switched the biologic agent for ustekinumab, with good
tolerance and high efficacy.
Downloads
References
European Medicines Agency. Summary of Product Characteristics Enbrel [acedido a 05 de agosto de 2019] Disponível em: https://www.ema.europa.eu/documents/product-information/enbrel-epar-product-information-en.pdf.
Cunnane G, Warnock M, Fye K, Daikh D. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. 2002;47:445-9. Doi: 10.1002/art.10535.
Zamora F, Podgaetz E, Dincer H. Nódulos pulmonares contraintuitivos en artritis reumatoide. Arch Bronconeumol. 2016;52:334-5. doi: 10.1016/j.arbres.2015.09.010.
Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa J, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-
-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41:256-64. doi: 10.1016/j.semarthrit.2010.11.002.
Wynn T. Fibrotic disease and the TH1/TH2 paradigm. Nat Rev Immunol. 2004;4:583-94.
Serban K, Muzoora M, Hage C, Lahm T. Distinct immunologic and radiographic patterns in etanercept-induced lung injury. Respir Med Case Rep. 2013;8:18-20. doi: 10.1016/j.rmcr.2012.12.002.
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
